Innovation Tracking Factbook 2016 - An Assessment of the Pharmaceutical Pipeline

  • ID: 3782920
  • Report
  • Region: Global
  • 70 Pages
  • CBR Pharma Insights
1 of 5
Pharmaceutical Companies Increasingly Looking to Innovate High-Risk, First-in-Class Products
"Innovation Tracking Factbook 2016- An Assessment of the Pharmaceutical Pipeline"" is a comprehensive, granular analysis of the 20,756 products currently in the pharmaceutical industry pipeline, from the Discovery stage through to Pre-registration and split into therapy areas and key indications.

This pipeline is also benchmarked against its size across each segment in 2015, and an assessment of the level of first-in-class innovation is provided. In addition, a detailed contextual analysis of the key drivers of this pipeline is provided, in addition to an assessment of companies present in the pipeline and historical deal value and volume.

Innovation, particularly the development of new products, is a crucial element of the pharmaceutical industry. The market is highly research-intensive, being deeply reliant on a high level of R&D investment and a strong product pipeline to maintain growth and ensure long-term revenue generation. Without successful innovation, which can be broadly defined as the market launch of novel therapeutic molecules that cost-effectively treat or cure diseases, the industry would face a substantial long-term decline in revenue.

A particular focus of this report is placed on analysis of the development of innovative drugs, specifically first-in-class innovation. Over recent decades, in addition to an increase in the yearly number of new chemical entity approvals by the FDA, the number and proportion of these approvals that were first-in-class at the time of approval have also increased. The proportion of first-in-class approvals has increased steadily each year since 1994, with the exception of the years 2005-2008, when the proportion was relatively high.

Scope

- What is the current size and composition of the pharmaceutical industry pipeline and how has it changed since Q1 2015? What can we learn from this?
- The largest therapy area, by a substantial margin, is oncology, and, with growth in the pipeline sizes for all major oncology indications since Q1 2015, this trend appears set to continue. Why is this the case?
- What is the overall advantage for companies including first-in-class product developments in their pipeline portfolio, rather than opting for better-characterized established molecular targets?
- What factors have been driving the increasing number of first-in-class product approvals over recent decades?
- What strategies have companies typically been pursuing with their pipeline portfolio, in terms of how diverse, specialized or innovative they have been? Specifically, what strategies have the top 25 pharmaceutical companies been following?
- What key discernible trends have appeared in the strategic consolidations landscape in the past decade and which disease areas have been most active?

Key Reasons to Purchase

This report will allow you to-
- Achieve an up-to-date understanding of the landscape of the overall pharmaceutical pipeline, on both a broad and granular level; this also provides a highly accessible reference which is useful in any pharmaceutical strategic decision making process
- Benchmark key therapy areas and indications in terms of the number of pipeline products and level of innovation, and assess one’s own strategic positioning against this backdrop
- Understand the contemporary role and importance of radical and incremental innovation within the various disease areas and indications
- Make key decisions about the role of innovation within one’s own pipeline portfolio

READ MORE
Note: Product cover images may vary from those shown
2 of 5
1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Increasing Cost of Drug Development
2.2 Most Drugs Fail to Recuperate R&D Costs
2.3 Contracting Life Cycles for Approved Products
2.4 The Case for First-in-Class Pharmaceutical Innovation
2.5 Conclusion

3 Assessment of the Pharmaceutical Industry Pipeline
3.1 Pipeline and Clinical Trials Landscape by Therapy Area
3.2 Pipeline by Stage of Development
3.3 Pipeline by Molecule Type
3.4 Key Therapy Areas by Indication
3.4.1 Oncology
3.4.2 Infectious Diseases
3.4.3 Central Nervous System
3.4.4 Immunology
3.5 Conclusion

4 Assessment of Innovation in the Pharmaceutical Industry Pipeline
4.1 First-in-Class Innovation by Stage of Development
4.2 Key Therapy Areas by Indication
4.2.1 Oncology
4.2.2 Infectious Diseases
4.2.3 Central Nervous System
4.2.4 Immunology
4.3 Conclusion

5 Company Analysis
5.1 Conclusion

6 Deals Analysis
6.1 Licensing Deals
6.2 Co-development Deals
6.3 Mergers and Acquisitions
6.4 Capital Raising

7 Appendix
7.1 References
7.2 Contact Us
7.3 Disclaimer

1.1 List of Tables
Table 1: Trends in Clinical Trial Protocol Complexity, 2000-2011
Table 2: Pipeline Products by Therapy Area, 2015-Q1 2016
Table 3: Number of Clinical Trials Initiated by Therapy Area, 2006-2015
Table 4: Pipeline Products by Therapy Area and Stage of Development
Table 5: Pipeline Products by Therapy Area and Molecule Type, Q1 2016
Table 6: First-in-Class Pipeline Products by Therapy Area, Q1 2015-Q1 2016
Table 7: First-in-Class Oncology Pipeline Products by Indication, Q1 2015-Q1 2016
Table 8: First-in-Class Infectious Diseases Pipeline Products by Indication, Q1 2015-Q1 2016
Table 9: First-in-Class Central Nervous System Disorder Pipeline Products by Indication, Q1 2015-Q1 2016
Table 10: First-in-Class Immunology Pipeline Products by Indication, Q1 2015-Q1 2016
Table 11: Licensing Deal Value and Volume, 2006-Q1 2016
Table 12: Number of Licensing Deals by Therapy Area, 2006-Q1 2016
Table 13: Aggregate Licensing Deal Value by Therapy Area ($m), 2006-Q1 2016
Table 14: Co-development Deal Value and Volume, 2006-Q1 2016
Table 15: Co-development Deal Volume by Therapy Area, 2006-Q1 2016
Table 16: Co-development Deal Value by Therapy Area ($m), 2006-Q1 2016
Table 17: Merger and Acquisition Deal Value and Volume, 2006-Q1 2016
Table 18: Capital Raising Value and Volume, 2006-Q1 2016

1.2 List of Figures
Figure 1: US Life Expectancy by Sex, 1950-2015
Figure 2: FDA Approvals, 1987-2015
Figure 3: Average Cost of Developing a Novel Drug ($m), 1970-2015
Figure 4: Average Lifetime Sales after Tax by Decile ($m), 1990-1994
Figure 5: Drivers of Shortened Pharmaceutical Product Life Cycles, 1970-2003
Figure 6: FDA Approvals by Innovation Status, 1987-2015
Figure 7: Average Sales of First-in-Class and Non-First-in-Class Products After Launch ($m), 2006-2014
Figure 8: Average Projected Sales of First-in-Class and Non-First-in-Class Products Launched in 2015 ($m), 2016-2022
Figure 9: Pipeline Products by Stage and Molecule Type, Q1 2016
Figure 10: Pipeline Products by Therapy Area, Q1 2016
Figure 11: Overall Pipeline, Number of Products and Pipeline Growth by Therapy Area, Q1 2015-Q1 2016
Figure 12: Number of Clinical Trials Initiated, 2006-2015
Figure 13: Number of Clinical Trials Initiated by Therapy Area, 2006-2015
Figure 14: Pipeline Products by Therapy Area and Stage of Development (%), Q1 2016
Figure 15: Pipeline Products by Therapy Area and Stage of Development Q1 2016
Figure 16: Pipeline Products by Therapy Area and Molecule Type, Q1 2016
Figure 17: Pipeline Products by Therapy Area and Molecule Type, Q1 2016
Figure 18: Oncology Pipeline Products by Indication, Q1 2016
Figure 19: Oncology Pipeline, Number of Products by Indication, Q1 2015-Q1 2016
Figure 20: Infectious Disease Pipeline, Number of Products by Indication, Q1 2016
Figure 21: Infectious Disease Pipeline, Number of Products and Pipeline Growth by Indication, Q1 2015-Q1 2016
Figure 22: Central Nervous System Pipeline, Number of Products by Indication, Q1 2016
Figure 23: Central Nervous System Pipeline, Number of Products and Pipeline Growth by Indication, Q1 2015-Q1 2016
Figure 24: Immunology Pipeline, Number of Products by Indication, Q1 2016
Figure 25: Immunology Pipeline, Number of Products and Pipeline Growth by Indication, Q1 2015-Q1 2016
Figure 26: Pipeline Products by Therapy Area and Proportion of Established and First-in-Class Products, Q1 2016
Figure 27: First-in-Class Pipeline, Number of Products and Pipeline Growth by Therapy Area, Q1 2015-Q1 2016
Figure 28: First-in-class Pipeline Products by Therapy Area and Stage of Development, Q1 2016
Figure 29: First-in-Class Oncology Pipeline Products by Indication, Q1 2016
Figure 30: First-in-Class Oncology Pipeline, Number of Products and Pipeline Growth by Indication, Q1 2015-Q1 2016
Figure 31: First-in-Class Infectious-Diseases Pipeline Products by Indication, Q1 2016
Figure 32: First-in-Class Infectious Disease Pipeline, Number of Products and Pipeline Growth by Indication, Q1 2015-Q1 2016
Figure 33: First-in-Class Central Nervous System Disorder Pipeline Products by Indication, Q1 2016
Figure 34: First-in-Class Central Nervous System Disorder Pipeline, Number of Products and Pipeline Growth by Indication, Q1 2015-Q1 2016
Figure 35: First-in-Class Immunology Disorder Pipeline, Number of Products by Indication, Q1 2016
Figure 36: First-in-Class Immunology Pipeline, Number of Products and Pipeline Growth by Indication, Q1 2015-Q1 2016
Figure 37: Companies by Number of Pipeline Products, Q1 2016
Figure 38: Number of Therapy Areas Covered by Company Pipelines, Q1 2016
Figure 39: Companies by Number of First-in-Class Products, Q1 2016
Figure 40: Top 25 Pharmaceutical Pipeline Portfolios by Stage of Development, Q1 2016
Figure 41: Top 25 Pharmaceutical Pipeline Portfolios by Therapy Area, Q1 2016
Figure 42: Top 25 Pharmaceutical Pipeline Portfolios, First-in-Class Products by Therapy Area, Q1 2016
Figure 43: Licensing Deal Value and Volume, 2006-Q1 2016
Figure 44: Number and Value of Licensing Deals by Therapy Area, 2006-2015
Figure 45: Co-development Deal Value and Volume, 2006-Q1 2016
Figure 46: Co-development Deal Value and Volume by Therapy Area, 2006-2015
Figure 47: Merger and Acquisition Deal Value and Volume, 2006-Q1 2016
Figure 48: Capital Raising Value and Volume, 2006-Q1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
With the cost of bringing a single novel drug to market estimated to be $2.6 billion in 2015, pharmaceutical companies are increasingly looking towards developing first-in-class treatments to maximize revenue and stay ahead of competition.

This report states that the growth in drug research and development (R&D) costs appears to stem from an increased clinical failure rate and emphasis on proving superiority over comparator drugs in technology assessments, as well as an increasing level of sophistication from payers when assessing the cost-effectiveness of drugs.

Higher-risk programs for innovative first-in-class products remain attractive and have led to some of the most clinically and commercially successful products over the past decade, and the 4,964 first-in-class products currently in development represent 37.9% of pharmaceutical pipeline products with a disclosed molecular target.

Overall, ‘me-too’ drugs, which are structurally very similar to already-established drugs, have traditionally been highly commercially and clinically successful. These products continue to provide a well-established pathway for promising product developments due to a lower risk profile based on safer and more cost-effective incremental innovation.

This report provides analysis of the 20,756 products currently in the pharmaceutical industry pipeline, from the Discovery stage through to Pre-registration and split into therapy areas and key indications. It also includes a detailed contextual analysis of the key drivers of this pipeline, along with an assessment of companies present in the pipeline and historical deal value and volume.

Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll